نتائج البحث - Ya-Ning Zhu

Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG12C mutation in China and the United States حسب Ya-Ning Zhu, Meng Tang, Ke-Xin Sun, Bei Gao, Xian-Peng Shi, Peng Zhang

Connect to this object online.